PLGLB2 Antibody (62.P): sc-130390

PLGLB2 Antibody (62.P) is a mouse monoclonal IgG1 kappa light chain antibody that detects PLGLB2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-PLGLB2 antibody (62.P) is available as a non-conjugated format. PLGLB2 protein, also known as plasminogen-like B2 or PLGP1, is a 96 amino acid protein that plays a crucial role in the fibrinolytic system, particularly in blood clot dissolution regulation. PLGLB2 resembles the N-terminal plasminogen activation peptide, which releases during plasminogen conversion to plasmin, the active enzyme responsible for breaking down fibrin in blood clots. PLGLB2′s unique structure allows potential binding to lysine binding sites in plasminogen kringle domains, which may interfere with fibrin or α-2 antiplasmin binding, thereby influencing proteolytic activity localization at sites critical for extracellular matrix remodeling. This function maintains proper tissue homeostasis and prevents excessive fibrosis or scarring, making PLGLB2 an important target for research in cardiovascular diseases and other conditions related to abnormal clotting and tissue repair.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PLGLB2 Antibody (62.P) References:

1. Expression of plasminogen-related gene B varies among normal tissues and increases in cancer tissues.  |  Tateno, T. and Ichinose, A. 1999. FEBS Lett. 445: 31-5. PMID: 10069369
2. Homologous plasminogen N-terminal and plasminogen-related gene A and B peptides. Characterization of cDNAs and recombinant fusion proteins.  |  Lewis, VO., et al. 1999. Eur J Biochem. 259: 618-25. PMID: 10092845
3. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.  |  Stack, MS., et al. 1999. Biochem J. 340 (Pt 1): 77-84. PMID: 10229661
4. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.  |  Zhang, LP., et al. 1999. J Hepatol. 31: 703-11. PMID: 10551395
5. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells.  |  Wickström, SA., et al. 2001. Cancer Res. 61: 6511-6. PMID: 11522648
6. Interaction of plasminogen-related protein B with endothelial and smooth muscle cells in vitro.  |  Morioka, H., et al. 2003. Exp Cell Res. 287: 166-77. PMID: 12799192
7. A plasminogen-related gene is expressed in cancer cells.  |  Weissbach, L. and Treadwell, BV. 1992. Biochem Biophys Res Commun. 186: 1108-14. PMID: 1379800
8. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.  |  Costantini, V., et al. 1996. Cancer. 77: 1079-88. PMID: 8635127
9. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.  |  Christensen, L., et al. 1996. Int J Cancer. 66: 441-52. PMID: 8635858